Photodynamic therapy (PDT) as a cancer treatment is notable for its quite low side effect~ in comparison with those of chemotherapy and radiotherapy. However, the accumulation of porphyrin derivatives used in PDT into tumor tissues is rather low. Sinee long-circulating liposomes are known to accumulate passively into tumor tls..\ues, we liposomalized a porpbyrin derivative, benlOporphyrin derivative monoacid ring A (BPD.MA), and used these liposomes to investigate the usefulnes.~ of PDT for tumor-bearing mice. BPD ... MA was liposomalized into glueuronate-modified liposomes, which are known to be lon2-drculating. These liposomes were injected i.v. into Raible mice bearing Meth A sarcoma, and tumor regression and survival time were monitored after irradiation with laser light. Tumor regression and complete curing of tumor (80°;'~ cure rate by the treatment with 6 rng/kg BPD-MA) were observed when long circulating liposomalized BPD-MA was injected Hnd laser-irradiated. In contrast, only a 20°,lt1 cure fide was obtained when the animals were treated with BPD-MA solution or BPD-MA entrapped in conventional Jiposomes. These re~ults §uggest that a Iong-circulating IiposomaJ formulation of photo-sensitive agents is useful for PDT.
Photodynamic therapy (PDT) aims at causing selective damage to tUlnor tissues without the serious side effects often experienced with both chemotherapy and radiation therapy.l-3) Furthermore. PDT is useful against most types of malignant cells. 4 ·· 7) Tn PDT, systemically administered photosensitizers that tend Lo accumulate more rapid1y in tumor tissues than in normal ones are photochemically activated by irradiation with laser light of the appropriate wavelength. Photofrin®, a hematoporphyrin derivative, has heen used clinically, since it is retained in nearly all malignant lesions, and it shows significant antitumor activity with no prohibitive toxicity in animals or humans. However, effective penetration through tissues of 630-nm wavelength light. which activates Photofrin®. is limited because of adsorption of the light by natural chromophorcs. namely, oxyhemoglobin. Furthermore, Photofrin® causes prolonged skin photosensitivity in patients atler treatment. H) As one of the second generation drugs for PDT. a benzoporphyrin derivative (OPD) has been developed; it exhibits strong absorbance in the red and near infrared spectrum. Q) BPD has an excitation optimum of about 690 nm t 0) and has reduced skin phototoxici ty com pared with Photofrin®.ll) Benzoporphyrin derivative monoacid ring A (BPD-MA), a ch\orin-like compound. has been revealed to be a desirable photosensitizer; e.g .
• it becomes concentrated in tumor tissue quite highly and rapidly, with no residual photosensitizing activity after 24 h, 12) and effectively destroys Ml rhabdomyosarcoma 13 ) and LI210 leukemia 14) cells in murine tumor model systems.
The uptake of BPD-MA into tumor tissues is high compared with that into other tissues. The total uptake in tumor tissues is, however, still low in terms of percent of injected dose, which, per gram tumor tissue, is less than O.5'Yo. 15) furthermore, BPD is highly lipophilic and therefore requires a carrier, such as liposomcs. for effec-* To whom correspondence should be addressed.
tive delivery in animals and humans. In fact, Hposomal BPD-MA was more efficienl than the dimethyl sulfoxide (DMSO)-so]ubilized form when PDT was performed in tumor-bearing mice, alLhough liposon1al BPD-MA was transferred to lipoproteins after injection into model animats.
• 17 )
J jposomal encapSUlation of anti-cancer drugs has been shown to enhance their efficacy and to reduce the side effect of the drugs. 1 R. 1 Q) Since one of the di sad van tages of liposomal use is their trapping by the reticuloendothelial ~ystem (RES), many attempts have been made to prepare long-circulating liposomes that can avoid REStrapping. 20 23) Such liposomcs with a long·circulating property might extravasate through leaky endothelium to localize in tumor tissues, because the vasculature that develops in growing tumors is generally more permeable than normal vasculature. and lymph channels, which recover extravasated molecules, are little developed in tumor tissues. 24 . 2S ) For this purpose. we synthesized a glucuronate derivative, palmityl-o-glucuronide (PGlcUA). and observed that PGlcUA-liposomes have a long circulation time in normal mice and accumulate in the tumor tissue of tumor-bearing Inice.2(I) In the present study, therefore, we encapsulated BPD-MA in such long .. circulating liposomes to deliver it effectively to tumor tissues for PDT.
MATERIALS AND METHODS
Materials BPD-MA was the product of Quadra Logic Technologies, Inc. (Vancouver, B.C" Canada). Dipalmitoylphosphatidylcholine (DPPC). l-palmitoyl-2-olcoyl phosphatidy1choline (POpe), dipalmitoylphosphatidylglycerol (DPPG). and PGlcUA were the products of Nippon Fine Chemical Co., Ltd. (Takasago, Hyogo, Japan). Cholesterol (Chol) was purchased from Sigma (St.
Louis, MO).
Preparation of Liposomes Liposomes composed of DPPC, POPC.Chol, and BPD-MA with DPPG or PGIc-UA (l : I : 1 : 0.06: 0.5 as a molar ratio) were prepared as follows: Lipids and BPD-MA dissolved in ch1oroform/ methanol were dried under reduced pressure and stored in vacuo for at least ) h. Liposomcs (40.umol as DPPC) were produced by hydration of the thin lipid film with 2.0 ml of 0.3 M glucose and extruded through a polycarbonate memhrane filter with a IOO-nn1 pore size (Nucleoporc. Costar Co., Calnbridge. MA) after three t;yclcs of freeze-thawing. Liposomal preparation was conductcu under protection from light. BPD-MA was quantified by its absorhance at 430 nm after extraction by ethanol from a Iiposomal solution.
Tumor Implantation and in Villo Experiment Meth A sarcoma grown in the ascites of Balh/c maJe mice (Japan SLC. Shizuoka, Japan) under an appropr;atc schedu1e were diluted with saline to obtain 5 x 10 6 cells/ml suspension. Then. 0.2 ml of the sllspcnsinll was carefulJy injected subcutaneously into the poslerior flank of five-week-old Balb/c male mice. At day 6 c.1fter tumor implantation. where a is the largest and h the smaHest diameter. Tumor volume calculated by the formula is known to correlate well with actual tumor weight (r=O.980).17) Surviving mice were monitored more than 180 d.
RESULTS
Tumor Regres.~ion by Free or LiposomaJ BPD-MA after Irradiation with Laser Light Meth A sarcoma-bearing mice were injected i.v. with free BPD-MA or one of two kinds of liposomal BPD-MA. namely, BPD-MA in long-circulating liposomes or in conventional liposomes, and they were then kept in the dark for 5 h. Next, the tumor site was irradiated with 180 J/cm 2 of 690-nm laser light. Figure 1 shows the results when 2 mg/kg of BPD-MA was injected. As shown in the figure. the liposoma1 formulations. especially the iong-circu1aling liposomal formulation, were the most effective in reducing the cancer growth. When 6mg/kg of BPD-MA was injected, both the free drug and both kinds of liposomaJ formulations resulted in a drastic reduction in tumor growth, although tumor volume was hard to measure because of scarring. probably due to the healing process (data not shown): Essentia1ly no detectable tumor growth was observed until day 22 under the condition. Figure 2 ! after PDT (at day 10 after impJantation of Meth A sarcoma) with or withollt ]ong·circulating liposoma1 BPD-MA. As shown in Fig. 2b , PDT with PGlcUA-liposomal BPD-MA caused drastic regression of the tumors. Body Weight Change Caused by PDT of Free and Liposomal BPD-MA Next, we examined the side effects of PDT with liposomal BPD-MA. No weight loss in mice after PDT, which is one side effect criteria. was observed when mice were injected with 2 mg/kg free BPD-MA or 2mg/kg liposomal BPD-MA (data not shown). However, slight weight loss in mice after PDT was observed when mice were injected with 6 mgjkg free BPD-MA or 6 mg/kg liposomal BPD-MA, although part of this may have occurred due to the removal of scar tissue from the irradiation site during the hea1ing process. No weight loss was observed, either, in each case without laser irradiation (data not shown), suggesting that 6 mg/kg BPD-MA in either the free or Jiposomal form causes no severe side effects in mice without irradiation.
Survival Time of Tumor-Bearing Mice after PDT with Free or Liposomal BPD .. MA The survival time of Meth A sarcoma-bearing mice after the injection of free or tiposomal BPD-MA and irradiation with 180J/cm 2 of 690-nm laser light was monitored. As shown in Fig. 4 , PDT with PG1cUA-liposomal BPD-MA showed remarkable therapeutic efficacy compared with the other treatments. The results of control experiments either without laser-irradiation after the injection of 6 mg/kg BPD-MA in the long-circulating liposomal form or with irradiation after the injection of 0.3 M glucose solution indicated no prolongation of the survival time of tumor-bearing mice (data not shown. see Table 1 ). Table 1 summarizes the data obtained from the experiment. PDT with PGIcUA-liposomal BPD-MA resulted in a 4/5 cure rate for animals that were apparently tumor-free and remained alive throughout the experimental period (more than 180 d).
DfSCUSSION
Since PDT has a cytotoxic action on local tumors by irradiation with the appropriate light, this therapy has been attractive because of both its reduced side effects and its efficacy. Therefore, many attempts have been made to develop new photosensitizers that effectively accumulate in tumor tissue and show high therapeutic cflicacy. 2~,29) BPD-MA is one of these promising photosensitizers because of its high and rapid accumulation in tumor tissues after Lv. injection, followed by rapid elimination, which may reduce skin photosensitivity due to residual sensitizer, and also its absorbance optimum of about 690nm, which enables the penetration of light deeper into the tissues irradiated than that of shorter wave-length light. Because of the hydrophobicity of the compound, a liposomal fonnulation is required to deliver it. After the injection of liposomal BPD-MA, it may be transferred to lipoproteins and thereby be de1ivered to the target tissues. 16.17) One disadvantage of the use of BPD-MA is that the accumulation of this photosensitizer in tumor tissues is still quite low, namely, less than 0.5%. of the injected dose. B) An increase in the amount delivered to the tumor tissue would be expected to increase the efficacy of BPD-MA. Long-circulating liposomes serve as an ideal carrier to deJiver molecules to the tumor tissues because they may accumulate in tumor tissues passively up to several percent or more of the injected dose. Furthermore, BPD-MA is ready as such to be incorporated into the 1iposomal membrane. Therefore, we experimented with the liposomalization of BPD-MA in long-circulating liposomes. Since we had earlier developed a kind of long-circu]ating liposome by the use of glucuronic acid made hydrophobic, namely, PGlcUA, we incorporated BPD-MA into PGlc-VA-modified liposomes. And, actually, these liposomal formulations increased the therapeutic efficacy of PDT (Figs. 1, 4 . and Table 1 ). Furthermore, liposomal appJication may change the action site of the photosensitizers, since it is reported that free hematoporphyrin causes tumor necrosis due to vascular damage, whereas liposomal hematoporphyrin is directly toxic to neoplastic cells. 30) Tn this experiment, we used liposomes composed mainly of DPPC, pope, and cholestero1, since the liposomalization of BPD-MA is difficult to achieve without pope, a phospholipid that makes the lipid bilayer rather fluid. Therefore, it is possible that some BPD-MA molecules are transferred to lipoproteins from liposomes. However, the usefulness of this liposomal formulation is obvious. Thus, most of the BPD-MA might be delivered to tumor tissues in a liposomal form, although the precise distribution form of the BPD-MA was not examined.
In conclusion, the hydrophobic characteristics of BPD-MA make it a suitable compound for tiposomalization; in addition, the long-circulating liposomal formulation of 673 BPD-MA is useful for PDT, probably due to a high accumulation of such liposomes in tumor tissues. Also, it is possible that BPD-MA is more susceptible to photosensitization when it is incorporated into cells in a liposomal form than in a free form.
